Select Page


Lung Cancer Summit

Virtual Live Conference

from October 13: University Hospital Geneva

all lectures now available on demand!






Register HereGo To Meeting Now

Alfredo Addeo, MD
Alfredo Addeo, MD

Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

Solange Peters, MD-PhD
Solange Peters, MD-PhD

Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Following the great success of the virtual International Lung Cancer Summit (ILCS), we look forward to welcoming you to the 3rd edition of this interactive hybrid meeting. Similar to recent years, the ILCS will showcase latest discoveries and advances performed towards the treatment of lung cancer. The conference will leverage digital channels to provide with an exceptional outreach and opportunity for delegates from Medical Offices, Universities and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research.
The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from the USA, Spain, Ireland, Italy, South Africa, India and Switzerland.

This meeting is accredited and CME-certified by the Swiss Society of Medical Oncology with 5 credit points. Join us and get your certificate of attendance in the virtual meeting room.

5 SGMO CME Credits


Wednesday, 13 October 2021 – All Talks Now Available On Demand!

Indicated Time Zone: Central European Summer Time (CEST)


Welcome by Chairs

Solange Peters & Alfredo Addeo (Switzerland)


Latest treatment updates for frontline non-oncogene addicted NSCLC

Hossein Borghaei (USA)


How do we tailor treatments for later lines of therapy in the IO era

Giuseppe Banna (United Kingdom)


Integrating immunotherapy into localized NSCLC

Antonio Calles (Spain)


Open discussion & coffee break


Current standard of care and challenges in Small Cell Lung Cancer

Alessandra Curioni (Switzerland)


The art of balance: approaching immune-related adverse events in thoracic oncology

Jarushka Naidoo (Ireland)


State of the art in biopsy testing: the paths we set for lung cancer treatment

Stephen Finn (Ireland)


The latest on targeting EGFR+ Non-Small Cell Lung Cancer

Vanita Noronha (India)


ALK+ and ROS1: which TKI is suitable for which patient?

Alex Friedlaender (Switzerland)


Open discussion & coffee break


KRAS and HER2: Expanding the horizons for the treatment of lung cancer

Christine Lovly (USA)


RET, MET, NTRK… a new era for targeted therapies in all mutations?

Ronwyn van Eeden (South Africa)


Wrap up & Final Questions

Solange Peters & Alfredo Addeo (Switzerland)

The International Lung Cancer Summit 2021 was made possible with the kind support by our partners with no influence on the content:

MSD Logo
Eli Lilly Logo
AstraZeneca Logo
Amgen Logo
Novartis Logo
Bayer Logo
Janssen Logo
Pfizer Logo
Roche Logo
Takeda Logo
BMS Logo
Frontiers Logo
Sanofi Genzyme Logo
Merck Logo

Follow Us For The Latest News on Twitter & LinkedIn

Study suggests entrectinib prolongs survival in ROS1 #TKI naïve patients with ROS1 fusion-positive #NSCLC, with modest activity in patients with #CNS-only progression post-crizotinib 💊🫁

See the study by @alexdrilon, Salvatore Siena & colleagues ➡️

Image for the Tweet beginning: Study suggests entrectinib prolongs survival

Screening is important to identify high-risk individuals with #LungCancer so that they may have the best chances of curative treatment 🫁

See this new study highlighting key factors needed to allow for successful screening programs across Europe!



Image for the Tweet beginning: Screening is important to identify

Results from the JCOG0802 trial shed light on the clinical benefit of segmentectomy over lobectomy in terms of overall survival for early-stage #LungCancer 🫁

Check out the study in @TheLancet by Hisashi Saji, Hisao Asamura and colleagues ➡️


Image for the Tweet beginning: Results from the JCOG0802 trial

New study provides a resource of 46 PDX/CDX models derived from 33 donors with #SCLC, offering insight into the genomic & protein landscape of SCLC subtypes 🫁

#OpenAccess article in @NatureComms by @CaeserRebeccs, @triparnasen & colleagues ➡️


Image for the Tweet beginning: New study provides a resource

Results from the phase 3 #CheckMate816 trials suggest nivolumab plus chemotherapy increased event-free survival in people with #NSCLC 🫁

See the study in @NEJM by @FordePatrick, @DoctorJSpicer, @nicogirardcurie and colleagues ➡️

#LCSM #LungCancer

Image for the Tweet beginning: Results from the phase 3

🚨@NICEComms has approved #tepotinib for adults with advanced #NSCLC with METex14 skipping gene alterations!

It's estimated that between 1-2% of all adults with NSCLC in England have the disease with METex14 skipping alterations 🫁


#LCSM #LungCancer

Image for the Tweet beginning: 🚨@NICEComms has approved #tepotinib for
Load More...